Expression of DNA methyltransferases \textit{DNMT1}, \textit{3A}, and \textit{3B} in normal hematopoiesis and in acute and chronic myelogenous leukemia

Shin-ichi Mizuno, Takahito Chijiwa, Takashi Okamura, Koichi Akashi, Yasuyuki Fukumaki, Yoshiyuki Niho, and Hiroyuki Sasaki

Aberrant hypermethylation of tumor suppressor genes plays an important role in the development of many tumors. Recently identified new DNA methyltransferase (\textit{DNMT}) genes, \textit{DNMT3A} and \textit{DNMT3B}, code for de novo methyltransferases. To determine the roles of \textit{DNMT3A}, \textit{DNMT3B}, as well as \textit{DNMT1}, in the development of leukemia, competitive polymerase chain reaction (PCR) assays were performed and the expression levels of \textit{DNMTs} were measured in normal hematopoiesis, 33 cases of acute myelogenous leukemia (AML), and 17 cases of chronic myelogenous leukemia (CML). All genes were constitutively expressed, although at different levels, in T lymphocytes, monocytes, neutrophils, and normal bone marrow cells. Interestingly, \textit{DNMT3B} was expressed at high levels in CD34$^+$ bone marrow cells but down-regulated in differentiated cells. In AML, 5.3-, 4.4-, and 11.7-fold mean increases were seen in the levels of \textit{DNMT1}, \textit{3A}, and \textit{3B}, respectively, compared with the control bone marrow cells. Although CML cells in the chronic phase did not show significant changes, cells in the acute phase showed 3.2-, 4.5-, and 3.4-fold mean increases in the levels of \textit{DNMT1}, \textit{3A}, and \textit{3B}, respectively. Using methylation-specific PCR, it was observed that the \textit{p15\textsuperscript{INK4B}} gene, a cell cycle regulator, was methylated in 24 of 33 (72\%) cases of AML. Furthermore, AML cells with methylated \textit{p15\textsuperscript{INK4B}} tended to express higher levels of \textit{DNMT1} and \textit{3B}. In conclusion, \textit{DNMTs} were substantially overexpressed in leukemia cells in a leukemia type- and stage-specific manner. Up-regulated \textit{DNMTs} may contribute to the pathogenesis of leukemia by inducing aberrant regional hypermethylation. (Blood. 2001; 97:1172-1179)

© 2001 by The American Society of Hematology

Introduction

DNA methylation plays an important role in tissue- and stage-specific gene regulation,\textsuperscript{12} genomic imprinting,\textsuperscript{3,4} and X-chromosome inactivation,\textsuperscript{5} and has been shown to be essential for normal mammalian development.\textsuperscript{6} Recent studies have revealed that both global DNA hypomethylation and regional hypermethylation occur in tumorigenesis.\textsuperscript{7-9} Such aberrant DNA methylation is observed in a nonrandom, tumor type-specific manner.\textsuperscript{10} In particular, certain types of tumors show regional hypermethylation of CpG islands associated with the promoter regions of tumor suppressor genes, such as \textit{RB},\textsuperscript{11} \textit{VHL},\textsuperscript{12} \textit{p16\textsuperscript{INK4A}},\textsuperscript{13} and \textit{hMLH1}.\textsuperscript{14} Furthermore, the regional hypermethylation is often associated with the inactivation of the tumor suppressor genes.\textsuperscript{15} These data suggest that this epigenetic process has a pathogenic role in the clonal evolution of cancer.\textsuperscript{9}

In hematologic malignancies, aberrant DNA hypermethylation is thought to have relevance to leukemogenesis.\textsuperscript{16} For example, during the progression of chronic myelogenous leukemia (CML), the \textit{ABL} promoter of the \textit{BCR-ABL} fusion gene becomes significantly hypermethylated.\textsuperscript{17,18} Also, aberrant hypermethylation of the \textit{p15\textsuperscript{INK4B}} tumor suppressor gene is associated with its inactivation in at least half of the patients with acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML).\textsuperscript{19,20} Furthermore, hypermethylation of \textit{p15\textsuperscript{INK4B}} is observed concomitant with the disease progression in myelodysplastic syndrome (MDS).\textsuperscript{21} In addition to these tumor-related genes, a number of other genes are concurrently hypermethylated in AML,\textsuperscript{22} suggesting that there might be a dysregulation in the normal DNA methylation mechanism, by which the leukemic cells become predisposed to hypermethylation.

Until recently, only one mammalian DNA methyltransferase, \textit{DNMT1}, had been known, which has a higher maintenance DNA methylase activity rather than a de novo methylase activity in vitro.\textsuperscript{23} Recently, new mammalian DNA methyltransferase genes, \textit{DNMT3A} and \textit{DNMT3B}, have been cloned.\textsuperscript{24,26} Both the mouse \textit{Dnmt3a} and \textit{3b} (the orthologs of human \textit{DNMTs}) enzymes were shown to methylate hemimethylated and unmethylated DNA with equal efficiencies in vitro.\textsuperscript{24} In transgenic \textit{Drosophila melanogaster}, \textit{Dnmt3a} clearly exhibited de novo methylase activity, whereas \textit{Dnmt1} did not.\textsuperscript{27} Furthermore, a simultaneous inactivation of both \textit{Dnmt3a} and \textit{Dnmt3b} blocked the de novo methylation activity in embryonic stem cells and embryos,\textsuperscript{28} suggesting that these enzymes are the long sought de novo methyltransferases.
To understand the mechanisms underlying the aberrant, tumor type-specific hypermethylation, it is important to know the role of each DNA methyltransferase in the pathogenetic process. In colon cancer, increased DNMT1 expression has been demonstrated when compared with normal mucosa.20 In both colon and lung cancers, DNMT1 activity increases progressively, along with the advancement of their tumor stage.20,31 In hematologic malignancies, overexpression of DNMT1 was shown in 12 leukemia samples including AML, ALL, and MDS.22 As to DNMT3A and 3B, Robertson and coworkers have recently shown that both genes, as well as DNMT1, are up-regulated in some malignancies, such as bladder, colon, kidney, and pancreas tumors, though at different levels.23 Xie and colleagues have also reported the increased expression of all 3 DNMTs in several tumor cell lines.26

We have obtained DNMT3A and 3B complementary DNAs (cDNAs) independently from the other laboratories by database search. Then we have set out to study the roles of these enzymes in the pathogenesis of hematologic malignancies. In the present study, we report the expression levels of DNMT3A, DNMT3B, and DNMT1 in normal hematopoiesis, AML, and CML, studied by a competitive polymerase chain reaction (PCR) assay. Furthermore, in AML cases, we have investigated whether the expression levels of DNMTs are correlated with aberrant hypermethylation of the p15^INK4B tumor suppressor gene.

Materials and methods

Cloning of the human DNMT3A and 3B cDNAs

We performed a TBLASTN search32 of the dbEST database using modified mouse Dnmt1 motif IV sequences as queries and identified 3 matching mouse EST sequences (AA177277, AA116694, and AA155077) and 4 matching human EST sequences (W76111, N88352, AA361360, and AA216697). Two of the human EST clones deposited by the I.M.A.G.E. Consortium were obtained from Research Genetics and sequenced in their entirety. These sequences were identical to the corresponding part of the DNMT3A and DNMT3B cDNAs discovered by Robertson and colleagues23 and Xie and coworkers.26 PCR primers (Table 1) were prepared to amplify part of the catalytic domain of each DNMT3 cDNA. They were designed not to amplify genomic fragments, considering the exon-intron organization.

Clinical samples and cell lines

Heparinized peripheral blood and bone marrow cells were collected from patients with AML and CML, and from healthy donors after obtaining their informed consent. Immediately after harvest, mononuclear cells (MNCs) were isolated by sedimentation on Ficoll-Hypaque gradients. More than 90% of the MNC populations from AML and acute phase CML were leukemic blasts. Granulocyte fractions were collected from normal peripheral blood with Polymorphpherp (Nycomed Pharma, Oslo, Norway). Plastic-adherent cells from normal MNCs were used as the monocyte fraction. Peripheral lymphocytes were collected as nonadherent cells from normal MNCs, and T lymphocytes were enriched by negative selection, using Dynabeads M-450 CD19 (Dyna, Oslo, Norway). Purified T lymphocytes were stimulated with 2.5 μg/mL phytohemagglutinin (PHA; Sigma Chemical Co, St Louis, MO) for 72 hours and used as the activated T cells. CD34+ cells were isolated from normal bone marrow cells by positive selection, using Dynabeads M-450 CD34 (Dynab),34 and a flow cytometric analysis confirmed that more than 95% of the cells were CD34+. In addition to these cells, an Epstein-Barr virus (EBV)-transformed B-lymphocyte cell line (LCL), and 3 human leukemic cell lines (HL60, K562, and KU812) maintained under the standard conditions were used in this study.

In vitro assay for hematopoietic progenitors

Clonogenic progenitor assays were performed using the methylcellulose culture system.25 Five hundred CD34+ cells were cultured in 1 mL Iscove modified Dulbecco medium (GIBCO, Grand Island, NY) supplemented with 30% fetal calf serum (ICN Biochemicals, Osaka, Japan), 50 ng recombinant human interleukin-3 (rhIL-3), 50 ng recombinant human stem cell factor (rhSCF), 10 ng rhIL-6, 10 ng recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF), 10 ng recombinant human granulocyte CSF (rhG-CSF), 3 U recombinant human erythropoietin (all cytokines were from Kirin Brewery Co, Tokyo, Japan), 5 × 10^-3 M 2-mercaptoethanol, and 0.88% methylcellulose in 35-mm Nunc 171099 culture dishes (Nunc Inc, Naperville, IL) at 37°C under a humidified atmosphere with 5% CO2. After 14 days of culture, individual colonies were picked up using finely drawn-out Pasteur pipettes and processed for the reverse transcriptase-PCR (RT-PCR) analysis.

### Table 1. Oligonucleotide primers

<table>
<thead>
<tr>
<th>Oligonucleotide sequence</th>
<th>Nucleotide position* (exon number)</th>
<th>Target size (bp)</th>
<th>Competitor size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5′ GAPDH primer</td>
<td>5′-AGGCTCGAGAAGCCGGAAGCTTCATCAAT-3′</td>
<td>180-210 (exon 4)</td>
<td>500</td>
</tr>
<tr>
<td>3′ GAPDH primer</td>
<td>5′-TTCCGCTTCAGCACTGAGGTGGATCGG-3′</td>
<td>651-680 (exon 8)</td>
<td></td>
</tr>
<tr>
<td>5′ PCNA primer</td>
<td>5′-TCCTCCTCAGGAAGGTTGGAG-3′</td>
<td>27-50 (exon 1)</td>
<td>664</td>
</tr>
<tr>
<td>3′ PCNA primer</td>
<td>5′-CAGGACATGAGTCTGGCTGGG-3′</td>
<td>668-691 (exon 5)</td>
<td></td>
</tr>
<tr>
<td>5′ DNMT1 primer</td>
<td>5′-ACCCCTTCCACTCTCCGAGGCTT-3′</td>
<td>3242-3266 (exon 28)</td>
<td>335</td>
</tr>
<tr>
<td>3′ DNMT1 primer</td>
<td>5′-GTTGCCAGTGGGAACATCTAGGGG-3′</td>
<td>3551-3576 (exon 30)</td>
<td>551</td>
</tr>
<tr>
<td>5′ DNMT3A primer</td>
<td>5′-CAGCACGAACATATCAGGAGTG-3′</td>
<td>2970-2993†</td>
<td>2597-2620</td>
</tr>
<tr>
<td>3′ DNMT3A primer</td>
<td>5′-AGTGGACTGGGAAACCAAATACCC-3′</td>
<td>1942-1965 (exon 17)</td>
<td>190</td>
</tr>
<tr>
<td>5′ DNMT3B primer</td>
<td>5′-AGTGGAGTGAGTGTTTTTCTTTGTT-3′</td>
<td>2109-2132 (exons 18/19)</td>
<td>148</td>
</tr>
<tr>
<td>3′ DNMT3B primer</td>
<td>5′-GATTGAATTTCATCAACGCAGGG-3′</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The 5′ and 3′ primers of a pair for standard and competitive RT-PCR were designed for sequences in different exons so that they amplify only cDNA and not genomic DNA. Target size refers to the size of the PCR products from the gene transcripts and competitor size refers to the size of the PCR products from the competitor DNA. For methylation-specific PCR, primers designed by Herman and coworkers26 were used.

*The nucleotide sequence positions are relative to the ATG start.
†The exon-intron organization has not been determined.
‡M primer, a primer specific for methylated DNA.
§U primer, a primer specific for unmethylated DNA.
Isolation of RNA and RT-PCR analysis

Total RNA was extracted from various cell samples by acid the guanidine/phenol/chloroform method. To isolate RNA from the individually picked colonies, MS2 phage RNA (Boehringer Mannheim, Mannheim, Germany) was added as a carrier. First-strand cDNA was synthesized from 2 μg total RNA in a 50-μL reaction mixture containing random hexamers as primers by using a cDNA synthesis kit (Stratagene, La Jolla, CA). One μL cDNA mixture was brought into 25 μL 1 × PCR buffer, 10 mM Tris-HCl (pH 9.5), 50 mM KCl, 0.1% Triton X-100, 0.2 mM of each dNTP, 1.5 mM MgCl_, 10 pmol of each primer, and 2.0 U of Taq-DNA polymerase (Promega, Madison, WI). The primers used are listed in Table 1. PCR was performed in a Perkin Elmer GeneAmp PCR System 9600. Each PCR cycle consisted of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 1 minute. The PCR cycle numbers were 26 for GAPDH, 30 for DNMT1 and 3A, and 35 for DNMT3B (Figure 1). Under the conditions used, the cDNAs were exponentially amplified, and thus a semiquantitative estimation of the products was possible (data not shown).

Competitive PCR for quantitative analysis

To develop a competitive PCR assay for each gene, a competitor plasmid containing an extra DNA fragment in the target sequence was prepared. The GAPDH competitor plasmid was prepared by inserting a 210-bp SacII fragment from λ DNA into the unique SacII site of a 500-bp GAPDH cDNA fragment cloned in a plasmid vector PCR2.1 (Invitrogen, Groningen, The Netherlands). The PCNA competitor was prepared by cloning a 118-bp HaeIII fragment from dX174 DNA into the Stul site of a 664-bp PCNA cDNA fragment in pCR2.1. The DNMT1 competitor was prepared by inserting a 125-bp HindIII fragment from λ DNA into the HindIII site of a 335-bp DNMT1 cDNA fragment in a modified pBlueScriptSK+ vector, from which the HindIII site within the multicloning site had been deleted. The DNMT3A competitor was prepared by inserting a 117-bp BspPI fragment from λ DNA into the BspPI site of a 551-bp DNMT3A cDNA fragment in pCR2.1. The DNMT3B competitor was prepared by cloning a 141-bp ThhHBII fragment from pBR322 DNA into the NspI site of a 190-bp DNMT3B cDNA fragment in pCR2.1. All the above cDNA fragments were amplified from RNA of HL60 cells by RT-PCR.

The copy number of each competitor plasmid was determined and 3- or 4-fold consecutive dilutions were prepared. PCR was performed under the conditions described above. Series of PCR products were electrophoresed on a 1.5% agarose gel, stained with Vistra green (Amersham, Heidelberg, Germany), exposed to a FluorImager (Molecular Dynamics, Sunnyvale, CA) and quantitated using ImageQuant Software version 4.1 (Molecular Dynamics).

To calculate the initial amount of target transcripts, a range of dilutions in which the ratio of the products from the competitor to the products from the target was between 0.2 and 5.0 were taken. Then, log(products from competitor/products from target) was plotted against log(initial molecular amount of added competitor). A regression analysis revealed that this provided a near-linear curve in each case. The initial amount of target DNA was then determined from the equivalence point of the curve, where log(products from competitor/products from target) = 0. Expression levels of each DNMT were displayed as relative values by setting the mean of the levels in normal bone samples as 1, after normalizing the levels of DNMT by those of GAPDH or PCNA in the same sample.

Bisulfite modification and methylation-specific PCR

One μg genomic DNA was denatured in 50 μL 0.2 M NaOH at 37°C for 10 minutes and then added with 30 μL 10 mM hydroquinone (Sigma, St Louis, MO) and 520 μL 3 M sodium bisulfite (pH 5.0) (Sigma). Samples were incubated at 50°C for 16 hours under mineral oil. Modified DNA was purified using the Wizard purification resin and the Vacuum Manifold (Promega) and eluted into 50 μL water. After addition of 5.6 μL of 3 M NaOH (final 0.3 M), samples were let stand at room temperature for 5 minutes for final desulphonation. After ethanol precipitation, samples were dissolved in 50 μL water. Bisulfite treatment of DNA converts all unmethylated, but not methylated, cytosines to uracils. Based on the sequence differences resulting from this modification, methylation-specific PCR (MSP) was performed with the primer sets designed by Herman and colleagues (Table 1). PCR was performed in a 50-μL reaction mixture containing 100 ng bisulfite modified DNA, 1 × PCR reaction buffer (Promega), 0.2 mM of each dNTP, 1.5 mM MgCl_, 20 pmol of each primer, and 5% dimethylsulfoxide. Reactions were initiated by a hot start procedure: an initial denaturation at 95°C for 5 minutes, a further incubation at 98°C for 30 seconds, and then an addition of 2.0 U Taq-DNA polymerase (Promega). This was followed by 35 cycles of 30 seconds at 95°C, 30 seconds at 60°C, and 30 seconds at 72°C. A final extension was done at 72°C for 10 minutes. Products were loaded on a 2% agarose gel, stained with ethidium bromide, and observed under UV illumination.

Statistical analysis

To compare the DNMT levels between different sample categories, the Kruskal-Wallis test with the Bonferroni method for multiple comparisons was used. The strength of the association between the expression levels of each DNMT in different sample categories was calculated by the Spearman rank-correlation coefficient. The Mann-Whitney U test was used to compare the expression levels of DNMTs between 2 sample groups with or without p15NDAK2 methylation.

---

Figure 1. Expression of DNMTs in normal hematopoiesis and leukemia cell lines. Expression of DNMTs was assayed by a standard RT-PCR method in normal peripheral cells and bone marrow cells (A), resting and PHA-activated T cells (B), various colonies formed in hematopoietic progenitor assays (C), and 3 leukemia cell lines (D). With the cells other than the hematopoietic progenitor colonies, PCR amplification was performed for 26 cycles for GAPDH (a housekeeping control), 30 cycles for DNMT1 and 3A, and 35 cycles for DNMT3B (A,B,D). To amplify transcripts from the picked hematopoietic colonies, PCR was performed for 35 cycles for DNMT1, 3A, and GAPDH, and 40 cycles for DNMT3B.
Results

Expression of DNMTs in normal hematopoiesis and leukemia cell lines

We first examined whether the 3 DNMT genes were expressed in normal hematopoiesis. By a standard RT-PCR method, transcripts from all DNMTs were detected in peripheral neutrophils, monocytes, T lymphocytes, total bone marrow cells, CD34+ bone marrow cells, and various colonies derived from the CD34+ cells (Figure 1A-C). However, DNMT3B was expressed at levels lower than those of the other 2 genes, because 5 or more additional PCR cycles were required to obtain band signals comparable to those of DNMT1 and 3A. DNMT3B expression was especially low in differentiated cell populations such as neutrophils, monocytes (Figure 1A), and colonies of both the myeloid and erythroid lineages (Figure 1C). In contrast, total bone marrow cells and CD34+ cells expressed DNMT3B at somewhat higher levels (Figure 1A). We also examined 3 established leukemia cell lines HL60, KU812, and K562, by a standard PCR method and found that all 3 genes are respectively expressed at levels higher than those in normal hematopoiesis (Figure 1D). This suggests that overexpression of DNMTs might have some relevance to leukemic transformation (discussed later).

To obtain more accurate information on DNMT expression in normal hematopoiesis, we adopted the competitive PCR method using a synthetic mimic DNA as an internal control. Competitive PCR is an effective method to address an expression level of a certain gene, however, it has been reported that there could be some pitfalls for making an absolute estimation of targets. In this study, we demonstrated the results as fold-increase or decrease relative to the mean value of the same gene in control bone marrow cells after the normalization of the level of expression of each DNMT in a particular sample by GAPDH (a housekeeping control) or PCNA (a cell proliferation marker) in that sample (Figures 2 and 3). Examples showing actual PCR-amplified bands from both competitors and targets (Figure 2A) and graphs used to measure the expression levels of the transcripts (Figure 2B) are shown.

As shown in Figure 2C, expression of DNMT1 was rather uniform in various cell types except neutrophils, where its expression was relatively weak. DNMT3A was expressed at higher levels in T lymphocytes and neutrophils than in other cells although the differences were not so distinct (Figure 2C). It was characteristic, however, that CD34+ cells expressed DNMT3B at a level about 5-fold higher than that in normal bone marrow cells (Figures 2C and 1A). Furthermore, in contrast to the CD34+ cells, differentiated cells such as neutrophils and monocytes showed very low levels of DNMT3B expression (Figure 2C), indicating that this gene is dramatically down-regulated on hematopoietic cell differentiation, at least in some lineages. In addition, on activation with PHA, T lymphocytes showed a 2-fold increase in expression of DNMT1 and 3B (Figures 2C and 1B). Thus, all 3 DNMTs were expressed at detectable levels in normal hematopoietic cells, and their expression levels varied among cell types and differentiation conditions.

DNMTs were overexpressed in AML

To know the possible role of DNMTs in leukemogenesis, we analyzed their expression levels in 33 AML cases by competitive PCR. When normalized by the GAPDH levels, we observed 5.3-, 4.4-, and 11.7-fold mean increases in DNMT1, 3A, and 3B levels, respectively, compared with their levels in normal bone marrow cells (Figures 3A-C). However, the mean DNMT3B level in AML cells was compared with that in CD34+ cells, only 2.4-fold mean increase was observed (Figure 4C). It is noteworthy that among the 3 DNMT genes, DNMT3B showed the largest fold increase (11.7-fold; Figure 4C). When the mean DNMT3B level in AML cells was compared with that in CD34+ cells, only 2.4-fold mean increase was observed (Figure 4C). It is also interesting that all 4 M3 AML patients expressed lower levels of all DNMTs compared with the other subtypes (Figure 3A-C) although the number of cases studied was rather small.

Several reports pointed out that, in colon cancer, DNMTs appear to be overexpressed when the levels are normalized by those of a housekeeping gene but not overexpressed when corrected by those of cell proliferation marker genes. To exclude the possibility that the observed overexpression was due to accelerated cell proliferation of the AML cells, we corrected the levels of DNMTs by those of a cell proliferation marker PCNA (Figures 3D-F). As a result, the overexpression of DNMTs in 3 leukemia cell lines was clearly canceled (Figure 3D-F). However, the overexpression of all DNMTs in AML was not affected, or became even more evident, by this treatment (Figures 3D-F and 4D-F).

Because the extent of overexpression varied among the AML cases, we next investigated whether the 3 DNMT genes are overexpressed coordinately or independently. As shown in Figure 5, analysis of the expression levels in AML cases showed coordinate overexpression of DNMTs. When the values obtained by GAPDH correction were used, moderate correlations between DNMT1 and 3B (r = 0.464, P = .0065) and between DNMT3A and 3B (r = 0.568, P = .0006) were observed (Figure 5B,C). Furthermore, when the values by PCNA correction were used, we observed strong correlations between DNMT1 and 3A (r = 0.737, P < .0001), DNMT1 and 3B (r = 0.8339, P < .0001), and DNMT3A and 3B (r = 0.794, P < .0001) (Figure 5D-F).
Expression of DNMTs in CML

Chronic myelogenous leukemia is distinct from AML with its phasic clinical course that reflects the clonal evolution of leukemia cells. We investigated the expression levels of DNMTs in CML cells in each clinical phase. In contrast to AML, CML cells in the chronic phase expressed DNMTs at levels almost equal to those in normal bone marrow cells (Figures 3A-C and 4A-C). CML cells in the acute phase showed 3.2-, 4.5-, and 3.4-fold mean increases in the expression levels of DNMT1, 3A, and 3B, respectively, compared with their levels in normal bone marrow cells (Figures 3A-C and 4A-C). As in AML, the overexpression was not abolished even when the expression levels were corrected by PCNA (Figures 3D-F and 4D-F). It is of interest that the overexpression of DNMT3B was not evident in acute phase CML when the mean expression level was compared to that in CD34^+ cells (Figures 3C and 4C).

Methylation status of p15 INK4B and its correlation with DNMT overexpression in AML

It has been reported that a tumor suppressor gene, p15^{INK4B}, is frequently methylated and silenced in AML.\(^\text{19,20}\) Under the physiologic condition, expression of p15^{INK4B} is induced by transforming growth factor-β (TGF-β)\(^\text{14}\) and its protein product inhibits cell cycle progression.\(^\text{45}\) To explore the possible role of the DNMT overexpression in p15^{INK4B} methylation, we investigated the methylation status of the promoter region of this gene in our AML samples. By using methylation-specific PCR (Figure 6 represents the results),\(^\text{79}\) we observed that p15^{INK4B} was methylated in 24 (72%) of the 33 cases of AML (Table 2).

Interestingly, the AML cases with methylated p15^{INK4B} had a tendency to express higher levels of DNMT1, 3B, and potentially 3A, compared to the cases with unmethylated p15^{INK4B} (Figure 7). Although a statistically significant result was obtained only for DNMT1 (\(P = .0147\)), our findings suggest that the overexpressed DNMTs play a role in aberrant regional hypermethylation observed in AML.

Discussion

In the present paper, we have described the expression levels of the 3 DNMTs in normal hematopoiesis and leukemia cells. We first found that all DNMTs are expressed at detectable levels in normal hematopoietic cells. However, there are some genespecific features such as the down-regulation of DNMT3B on differentiation of hematopoietic progenitor cells and the induction of both DNMT1 and 3B on activation of peripheral T cells. These findings are of interest from the viewpoint of hematopoietic cell differentiation because it has been reported that some hematopoietic cell-specific genes, such as those coding for myeloperoxidase,\(^\text{46}\) globin,\(^\text{47}\) c-fms,\(^\text{48}\) and G-CSF receptor,\(^\text{49}\) are regulated by methylation in a lineage- and differentiation-dependent manner. In addition, it is known that differentiation of naive T cells into Th1 or Th2 cells is accompanied by changes in methylation at the genes coding for cytokines such as interferon-γ, IL-4, and IL-13.\(^\text{50}\) Furthermore, the importance of DNMT3B in the hematopoietic system has been also shown in ICF (immunodeficiency, centromeric instability, facial anomalies) syndrome. ICF syndrome is a rare autosomal recessive
disorder characterized by variable immunologic defects, such as a decreased number of lymphocytes and variable reduction in serum immunoglobulin levels, and recently, mutations were identified in DNMT3B in some ICF patients. Although how the defects in DNMT3B cause immunologic disorders remains unknown, it has been proposed that a loss of the proper methylation pattern may impair stage-specific gene regulation, resulting in interference with lymphocyte maturation. Therefore, the expression of DNMTs in hematopoietic cells is thought to have important roles for the differentiation process of blood cells.

We next found that all DNMTs are substantially overexpressed in most cases of AML when compared to normal bone marrow cells. Also, all DNMTs are expressed at higher levels in AML cells than in CD34+ cells, although this is statistically significant only for DNMT1. In addition, this overexpression observed in AML is not due to the accelerated proliferation of the leukemic cells because the data are basically unaffected even after corrected by the levels of a cell proliferation marker, PCNA. Furthermore, DNMTs were coordinately, not independently, up-regulated in AML cells. These results suggest that AML cells may possess higher maintenance and de novo methyltransferase activities than normal hematopoietic cells and these methyltransferases may contribute to the leukemogenesis by inducing aberrant methylation. Among the FAB subtypes, however, M3 (4 cases) showed only a minimal increase in the expression levels of DNMTs. Although this observation has to be confirmed in other M3 cases, it suggests that the possible roles of DNMTs in leukemogenesis vary among subtypes of AML.

In contrast to AML, CML shows phase-dependent expression of DNMTs. In the chronic phase, levels of DNMTs are not significantly different from those in normal bone marrow cells. However, CML cells in the acute phase expressed higher levels of DNMTs than normal bone marrow cells. DNMT1 and 3A, but not 3B, are also expressed at higher levels in acute phase CML cells than in CD34+ cells. Thus, the expression pattern of DNMTs in CML is more similar to that in AML than in normal hematopoietic cells.
DNMTs in CML was different from that of AML, suggesting that there might be different roles of DNMTs for leukemogenesis. The near-normal expression of DNMTs in chronic phase is compatible with the fact that the increased cell population in this phase is seemingly mature myeloid cells with essentially normal morphology and function. These results also suggest that DNMTs are not involved in the onset or maintenance of the chronic phase but could be associated with blast crisis. Because the ABL1 promoter nested within the BCR-ABL fusion gene has been demonstrated to be methylated with disease progression, it is conceivable that the overexpressed DNMTs methylate the ABL1 promoter region, and this in turn leads to clonal evolution. In the future study, it is important to know whether DNMTs are overexpressed prior to blast crisis in progenitor cells of CML.

The overexpressed DNMTs could be involved in the development of leukemia by inducing hypermethylation of tumor suppressor genes. We focused on p15INAK4B because this gene frequently becomes inactivated with disease progression in acute leukemia and MDS by hypermethylation of its 5′ CpG island. The protein product of p15INAK4B is a cell cycle regulator induced by TGF-β4 and involved in the inhibition of G1 phase progression. It has been reported that a loss of sensitivity of leukemia cells to growth inhibition by TGF-β is correlated with the inactivation of p15INAK4B. Consistent with the previous reports, this gene was methylated in 23 of the 33 (72%) cases with AML. Furthermore, we observed that the AML cases with hypermethylated p15INAK4B had a tendency to show higher levels of DNMT1 and 3B although the correlation was statistically significant only for DNMT1. These results suggest that up-regulated DNMTs could have roles for p15INAK4B methylation, although further studies will be required to test this possibility.

We studied the expression levels of DNMTs to gain a clue to their roles in aberrant regional hypermethylation in leukemia. Although DNMTs were substantially overexpressed in leukemia cells in a leukemia type- and stage-specific manner, the mechanism responsible for aberrant methylation remains to be solved. As for DNMT1, it has been proposed that a loss of p21 function in cancer facilitates the formation of DNA-DNMT1-PCNA complexes, resulting in aberrant methylation of CpG island. However, the mechanisms of recently identified de novo methyltransferases, DNMT3A and 3B, for aberrant methylation are largely unknown. In the study of D. melanogaster, induced expression of both Dnmt1 and Dnmt3a cooperated to establish and maintain methylation, resulting in increased methylation. As we have also observed coordinate overexpression of DNMTs in AML, there is a possibility that DNMTs act cooperatively in leukemia for the establishment of aberrant hypermethylation. It should also be noted that DNMT3B has at least 4 alternatively spliced transcripts, which are expressed in a tissue-specific manner. Because 2 of the splice variants lack the highly conserved sequence motifs in the methyltransferase catalytic domain, it will be important to know which splice variants are overexpressed in leukemia.

In conclusion, the DNMT genes were expressed constitutively in normal hematopoiesis and were overexpressed in some types of leukemia. The overexpressed DNMTs with maintenance or de novo methyltransferase activity may contribute to the pathogenesis of leukemia by inducing aberrant regional hypermethylation. Further studies will be needed to clarify the precise pathogenic roles of DNMTs in clonal evolution of leukemia and to develop therapeutic alternatives designed to suppress abnormal hypermethylation.

### Table 2. Summary of the methylation status of p15INAK4B in AML

<table>
<thead>
<tr>
<th>FAB type</th>
<th>No. of patients</th>
<th>No. of methylated cases (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0</td>
<td>1</td>
<td>0 (0)</td>
</tr>
<tr>
<td>M1</td>
<td>2</td>
<td>1 (50)</td>
</tr>
<tr>
<td>M2</td>
<td>11</td>
<td>6 (72)</td>
</tr>
<tr>
<td>M3</td>
<td>4</td>
<td>3 (75)</td>
</tr>
<tr>
<td>M4</td>
<td>3</td>
<td>3 (100)</td>
</tr>
<tr>
<td>M5</td>
<td>1</td>
<td>1 (100)</td>
</tr>
<tr>
<td>M6</td>
<td>2</td>
<td>2 (100)</td>
</tr>
<tr>
<td>M7</td>
<td>2</td>
<td>1 (50)</td>
</tr>
<tr>
<td>Mix</td>
<td>3</td>
<td>2 (66)</td>
</tr>
<tr>
<td>Total</td>
<td>29</td>
<td>21 (72)</td>
</tr>
</tbody>
</table>

Figure 7. Comparisons of the expression levels of DNMTs between the AML groups with or without p15INAK4B methylation. The levels of DNMTs were corrected by GAPDH (A-C) or PCNA (D-F). The level of DNMT1 corrected by GAPDH is significantly higher in the group with methylated p15INAK4B than in the group with unmethylated p15INAK4B (A) (P = .0147). Comparisons were made by the Mann-Whitney U test. M indicates methylated cases; U, unmethylated cases.

# Acknowledgment

The authors are indebted to Dr Naoko Kinukawa (Department of Medical Informatics, Faculty of Medicine, Kyushu University) for statistical analysis of the data.
References


BLOOD, 1 MARCH 2001 • VOLUME 97, NUMBER 5 EXPRESSION OF DNMT1, 3A, AND 3B IN LEUKEMIA 1179

From www.bloodjournal.org by guest on April 14, 2017. For personal use only.
Expression of DNA methyltransferases *DNMT1, 3A*, and *3B* in normal hematopoiesis and in acute and chronic myelogenous leukemia

Shin-ichi Mizuno, Takahito Chijiwa, Takashi Okamura, Koichi Akashi, Yasuyuki Fukumaki, Yoshiyuki Niho and Hiroyuki Sasaki